I'd add bid potential to the reasons for the high rating. There was already an abortive bid from Unilever just prior to the GSK demerger so I expect many people think that HLN may be taken out at some stage.
I retained my demerger HLN shares which have shown excellent growth, driving up the rating, though I'm just an income investor and it has demonstrated decent divi growth over its short independent existence. |
Buy backs
Debt leverage reduction
Annual organic revenue growth of 4-6%
Organic operating profit growth ahead of organic revenue growth
Net debt/adjusted EBITDA of around 2.5x
Dividend to grow at least in line with adjusted earnings |
Why is this trading at almost 25x earnings?
Far higher than peers. |
Jefferies raises Haleon price target to 450 (410) pence - 'buy' |
Maybe Pfizer punting around to unload their remaining stake ? |
Bond issues are bad news it seems |
Nice steady growth stock here, the dividend is small but as the debt comes off, the share price will gain momentum and the payout will grow.. :o).. |
:-)
September 10, 2024 11:41 AM EDT
BofA Securities analyst Victoria Petrova raised the price target on Haleon PLC (HLN:LN) to GBP4.40 (from GBP4.00)
streetinsider.com |
Hopefully that will firm up the share price! |
Haleon Launches Erectile Dysfunction Treatment Eroxon in US
September 03, 2024 at 09:54 am EDT
(MT Newswires) -- Haleon (HLN) said Tuesday that the erectile dysfunction treatment Eroxon is now available for Amazon pre-order in the US.
The company said Eroxon, a gel cleared by the US Food and Drug Administration to treat erectile dysfunction without a prescription, will be available at most major retailers next month. |
The Telegraph
Questor: Further FTSE 100 outperformance lies ahead for this maker of household names
Questor share tip: keep buying into its strong financial position and clear competitive advantage |
July 2022 these cost us 20% of our GSK shares and c273 pence each, a slow burner growth share if it can gain 50 pence a year and reduce debt leverage towards the target range, then ramp up the dividend payout towards 4-5%, another keep for life stock, I would say buy the dips but there has not been any notable ones so it looks like a case of averaging up.. :o)
02.08.2023 - 3.4X net debt/adjusted
29.02.2024 - 3.0X net debt/adjusted EBITDA
01.08.2024 - 2.9X net debt/adjusted EBITDA
Guidance target of 2.5X net debt/adjusted EBITDA
Dividend to grow at least in line with adjusted earnings
Organic revenue growth 4-6% |
xd tomorrow morning for the 2p dividend |
Berenberg raises Haleon price target to 447 (410) pence - 'buy' |
#Philander, same and add on the dips, another keeper for life as they deleverage the balance sheet and ramp up the dividend payout.. :o) |
Happy to hold. |
2p interim dividend. |
Surely another placing coming with the shares at this level |
Post demerger closing high. |
Results next thursday. |
I've now switched over to Haleon's Aquafresh toothpaste and Corsodyl Daily mouthwash .
Very good indeed :-) |
Haleon PLC (LSE:HLN, NYSE:HLN) first half/second quarter results on 1 August should be the last of ‘noise and volatility’ this year, suggests broker Jefferies.
From here on, it should be a normalised base of sales says the US bank, which expects volumes and product mix to underline it can be a 4-6% organic growth business.
Second quarter underlying volume is likely to be more than 3%, it adds and is a buyer with a 385p target.
Deutsche Bank has a lower target of 340p for the Sensodyne maker, which was recently reduced down from 345p, and a hold rating based on its current rating relative to the sector.
“If we apply the Colgate forward 12m PE to Oral Care the remainder is on 14x 12-month earnings, which would be too low if cold & flu is strong.
“We see a re-rating as centred on this currently.”
proactiveinvestors.co.uk |
Accelerate debt reduction, hit the net debt/EBITDA ratio target then hike the dividends.. :o) |
Register for streaming realtime charts, analysis tools, and prices.
Hot Features
Premium
